Cancer Care


Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)or T-cell Lymphoblastic Lymphoma
Principal Investigator (?)
Study Number
This randomized phase III trial is studying different combination chemotherapy regimens and
their side effects and comparing how well they work in treating young patients with newly
diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used
in chemotherapy work in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Giving more than one drug (combination
chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy
regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell
lymphoblastic lymphoma.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.